Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …

Purpose Recent reports have described a spectrum of uncommon findings of intraocular
inflammation (IOI), retinal vasculitis and/or retinal vascular occlusion in patients with …

Importance Limited data exist on the real-world safety outcomes of patients with neovascular
age-related macular degeneration treated with brolucizumab (Beovu). Objective To …

Background Brolucizumab has recently been approved in Europe as a novel treatment for
patients with neovascular age-related macular degeneration (nAMD). We report on early …

Background Intraocular inflammation is an uncommon but potentially vision-threatening
adverse event related to anti-VEGF therapy. This is of increasing importance given both the …

We evaluated the efficacy and safety of loading phase treatment with intravitreal
brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 …

Intravitreal injections continue to be one of the most commonly performed procedures by
ophthalmologists. Although the injections are generally well tolerated, sight-threatening …

Importance Outcome data are limited regarding early experience with brolucizumab, the
most recently approved anti–vascular endothelial growth factor (VEGF) agent for the …

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a
commonly used therapy for numerous retinal diseases. The most commonly used of these …

Purpose To analyze the risk factors associated with emerging intraocular inflammation (IOI)
after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration …